CLR Medical

CLR Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CLR Medical is a private medical device company focused on solving the clinical problem of retained hemothorax through its innovative irrigation system. Its core technology platform consists of two complementary, patented devices: the CLR Irrigator, an ergonomic suction/irrigation tool for one-handed lavage, and the CLR Port, an access port that allows for repeated sterile irrigation without breaking the closed drainage circuit. The company is commercial-stage, targeting adoption in hospital trauma and thoracic surgery settings to improve patient outcomes and reduce healthcare costs associated with complications from retained blood. Leadership is led by an engineer-founder with a focus on customer-driven design.

TraumaThoracic Surgery

Technology Platform

A proprietary, integrated system for closed thoracic irrigation consisting of the CLR Irrigator (a one-handed suction/irrigation device) and the CLR Port (an in-line access port for sterile, repeated lavage without breaking the drainage circuit).

Opportunities

Significant opportunity to reduce healthcare costs by preventing complications from retained hemothorax, potentially reducing need for more invasive surgeries like VATS.
The platform's design allows for potential expansion into irrigation procedures for other body cavities or complex fluid collections.

Risk Factors

Commercial adoption risk in convincing hospitals to change standard protocols and purchase new equipment.
Competition risk from larger medical device companies that could develop similar solutions.
Reimbursement and clinical evidence risk, as widespread adoption depends on robust data proving improved outcomes and cost-effectiveness.

Competitive Landscape

Competes against makeshift irrigation setups using syringes and stopcocks, which are the current standard but are cumbersome and break the sterile circuit. Also faces indirect competition from alternative treatments for retained hemothorax like intrapleural fibrinolytic therapy (e.g., tPA) and VATS. No direct, branded competitor offering a dedicated integrated irrigation system was identified.